Beyond The Numbers: 11 Analysts Discuss ACADIA Pharmaceuticals Stock

Benzinga Insights

September 29, 2025

Benzinga

In the preceding three months, 11 analysts have released ratings for ACADIA Pharmaceuticals (NASDAQ: ACAD), presenting a wide array of perspectives from bullish to bearish.

Latest Ratings for ACAD

Date	Firm	Action	To
Mar 2022	Cantor Fitzgerald	Maintains	Overweight
Mar 2022	Goldman Sachs	Maintains	Neutral
Mar 2022	Mizuho	Maintains	Neutral

View More Analyst Ratings for ACAD

View the Latest Analyst Ratings

Market Impact

These Analysts Slash Their Forecasts On Paysafe Following Downbeat Q3 Earnings

November 14, 2025

Benzinga

Market Impact

Eric Trump Praises Bitcoin — But ABTC Faces Brutal Drop To $3.50

November 14, 2025

Benzinga

Market Impact

Ardent Health Analysts Cut Their Forecasts After Weak Q3 Earnings

November 14, 2025

Benzinga

Market Impact

Tuya Accelerates AI Strategy

September 5, 2025

Benzinga

Market Impact

BioNTech Advances On Positive Phase 3 Breast Cancer Drug Data

September 5, 2025

Benzinga

Market Impact

This Twilio Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

September 5, 2025

Benzinga

Markets

There Are Now More ETFs in US Than There Are Individual Stocks

August 25, 2025

Bloomberg

Equities

Is AeroVironment Stock a Buy, Sell, or Hold for September 2025?

August 31, 2025

Barchart

Foreign Exchange & Fixed Income

Even More Headlines for Gold!

September 4, 2025

Barchart

Enjoy premium content in your inbox.

You're in! Check your email to learn more.

Oops! Something went wrong while submitting the form.

Beyond The Numbers: 11 Analysts Discuss ACADIA Pharmaceuticals Stock

Latest Ratings for ACAD

More from

Benzinga

More

Market Impact

Articles

Trending News

Enjoy premium content in your inbox.

News

Tools

More

Follow